Vertex Partners With AbCellera for $28M Autoimmune T-Cell Engager Collaboration
Deals·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Vertex Pharmaceuticals has entered into a partnership with AbCellera, paying $28 million upfront for access to its T-cell engager platform. This collaboration aims to develop treatments for autoimmune conditions and adds to Vertex's efforts to diversify beyond its cystic fibrosis medicines.
The deal marks AbCellera's second client this summer, highlighting a growing trend of partnerships focused on innovative T-cell engagers. This strategic move is seen as a significant opportunity for Vertex to expand its business portfolio.
VertexAbCellera
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.”
biopharma dive — AbCellera, Vertex partner on next-gen T-cell engagers“Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.”
fierce biotech — <a href="/biotech/vertexs-latest-autoimmune-tce-play-involves-28m-upfront-abcellera" hreflang="en">Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera</a>